Cover Image
Read Now

CADTH Canadian Drug Expert Committee recommendation: Glecaprevir / Pibrentasvir (Maviret -- Abbvie Corporation) indication : chronic hepatitis C virus infection

The CADTH Canadian Drug Expert Committee (CDEC) recommends that glecaprevir/pibrentasvir (GP) be reimbursed for the treatment of adult patients with HCV genotype 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis, including patients with HCV genotype 1 infection who were previously...

Full description

Bibliographic Details
Corporate Authors: CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format: eBook
Language:English
Published: Ottawa (ON) Canadian Agency for Drugs and Technologies in Health 2018, January 23, 2018
Edition:Version 1.0
Series:CADTH common drug review
Subjects:
Insurance, Health, Reimbursement
Canada
Antiviral Agents / Economics
Cost-benefit Analysis
Quinoxalines / Therapeutic Use
Hepatitis C, Chronic / Drug Therapy
Sulfonamides / Therapeutic Use
Online Access:
Collection: National Center for Biotechnology Information - Collection details see MPG.ReNa
Description
Summary:The CADTH Canadian Drug Expert Committee (CDEC) recommends that glecaprevir/pibrentasvir (GP) be reimbursed for the treatment of adult patients with HCV genotype 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis, including patients with HCV genotype 1 infection who were previously treated with either a regimen of NS5A inhibitor or with a NS3/4A protease inhibitor but not with both classes of inhibitors
Item Description:"Final."
Physical Description:1 PDF file (7 pages)

Similar Items